17 September 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
SRI Research Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further update on its work with SRI International ("SRI").
Further to the Company's announcement on 20 August 2024, the Company has now successfully demonstrated that the selected cargo, when combined with Nuvec® and SRI's Fox Three Molecular Guidance System ("MGS"), is performing as expected and has therefore completed the first stage of its collaboration project with SRI. More information will be released soon.
Find more information and an additional video by Nigel Theobald, CEO and submit any questions via the N4 Pharma investor hub: https://investors.n4pharma.com/link/MrDmnP.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We have now shown that not only is Nuvec® capable of modification with a ligand to target specific cells, but also that the combined new Nuvec® nanoparticle retains its ability to knockdown the target gene.
"We will add this information to our combined marketing pitch deck and both SRI and N4 Pharma will present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs."
For more information please contact:
|
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To hear more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44(0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope |
Tel: +44(0)20 3657 0050 |
|
|
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
